Enveric Biosciences Plans Reverse Stock Split
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Enveric Biosciences ( (ENVB) ).
Enveric Biosciences recently addressed its non-compliance with Nasdaq’s stockholders’ equity requirement by entering into warrant exercise inducement agreements, resulting in gross proceeds of approximately $2.2 million, which the company believes brings its stockholders’ equity above the required $2.5 million threshold. However, the company also received a delisting notice due to its stock price falling below $1.00 per share for 30 consecutive days, prompting a planned reverse stock split at a 1-for-12 ratio to regain compliance, effective October 28, 2025.
The most recent analyst rating on (ENVB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.
Spark’s Take on ENVB Stock
According to Spark, TipRanks’ AI Analyst, ENVB is a Underperform.
Enveric Biosciences faces significant financial difficulties, with no revenue and ongoing losses, which heavily impacts its overall score. The technical indicators suggest a bearish trend, adding to the negative outlook. The valuation component is challenging due to negative earnings, making the stock less attractive. Overall, the company’s financial instability is the most significant factor affecting its stock score.
To see Spark’s full report on ENVB stock, click here.
More about Enveric Biosciences
Enveric Biosciences is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company leverages a differentiated drug discovery platform and a library of protected chemical structures to advance a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Its lead candidate, EB-003, aims to deliver fast-acting, durable antidepressant and anxiolytic effects.
Average Trading Volume: 495,416
Technical Sentiment Signal: Sell
Current Market Cap: $4.22M
For detailed information about ENVB stock, go to TipRanks’ Stock Analysis page.
